Furthermore, as indicated in the review by Kumar et al.,2 MRGPRX2 antagonists should be further explored in detail in preclinical and clinical studies in other chronic inflammatory diseases (i.e. atopic dermatitis, chronic prurigo and rosacea) and chronic pruritus, diseases that have previously not been considered to be MC‐dependent. Here, MRGPRX2 is linked to rosacea.